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The effect of waiting time to surgery on survival in pancreatic cancer patients is unclear. We 
examined this association in a nationwide population-based cohort study. 
 
Materials and Methods: 
A nationwide population-based cohort study of all patients undergoing surgery for pancreatic 
cancer (resection or a palliative procedure) registered in the Danish Pancreatic Cancer Database 
from May 2011 to May 2016. We defined waiting time to surgery in two ways: 1) from the date of 
entry into the National Cancer Pathway to the date of surgery and 2) from the date of the last 
preoperative computed tomography (CT) or positron emission tomography (PET-CT) scan to the 
date of surgery. Waiting time was grouped into three groups: <28 days (<4 weeks), 28-55 days (4-
8 weeks), and ≥56 days (≥8 weeks). We calculated median survival with associated 95% 




We included 873 patients. Mean age was 67 years (range: 35-86 years). Resection was performed 
in 701 patients (80%); the remaining 172 patients (20%) underwent an explorative laparotomy or 
palliative surgery. 652 patients (75%) had a registration in the National Cancer Pathway (median 
waiting time: 31 days, and 818 patients (94%) had registration of a preoperative CT or PET-CT 
scan (median waiting time: 32 days). We saw similar resection rates (~80%) and median survival 
(~22 months) in all thee groups. 
 
Conclusion: 


































Pancreatic cancer is a highly fatal malignancy and projected to be the second leading cause of 
cancer-related deaths by 2030.[1] The majority of pancreatic cancer patients present with 
unresectable disease at the time of diagnosis.[2] As surgery is the only chance of cure, 
irresectability has a profound effect on the prognosis, leading to a dismal 5-year survival rate of 
less than 10%.[3] 
 In cancer surgery, waiting time from diagnosis to surgery is perceived to be an important 
quality indicator. In Denmark, national measures to facilitate prompt cancer surgery has been 
implemented, such as the National Cancer Pathway.[4] These measures are, however, associated 
with substantial costs. Furthermore, it is unclear if survival from pancreatic cancer is influenced by 
the time elapsed between diagnosis and surgery. Previous studies have suggested that waiting 
time to surgery does not alone influence survival.[5-7] However, these studies were all conducted 
in small populations, and findings from one of the studies were ambiguous.[6] In contrast, a major 
cohort study from the United States found that patients operated in the period one to two weeks 
following diagnosis had a worse survival compared with the rest of the population. 
On the one hand, increasing waiting time may render the tumor unresectable, as most 
pancreatic cancers have an aggressive biology.[3] On the other hand, political demands to lower 
the waiting time may impose unresolvable burdens on healthcare systems. Therefore, to guide 




2. MATERIALS AND METHODS 
2.1 Setting and data sources 
We conducted a nationwide, population-based cohort study of all patients undergoing surgery for 
pancreatic cancer (resection or a palliative procedure) registered in the Danish Pancreatic Cancer 














in 2011 and contains information such as date of diagnosis, tumor stage, comorbidity, and cancer-
directed treatment.[8] In 2014, the completeness of data in the Danish Pancreatic Cancer 
Database was 83%. Since then, both historic and new data in the Danish Pancreatic Cancer 
Database has been enhanced with data from the Danish Civil Registration System,[9] the Danish 
National Pathology Registry,[10] and the Danish National Patient Registry.[11] Information from 
these registries can be linked at an individual level using the civil personal registration number, 
which is a unique 10-digit identification number assigned to all Danish residents at birth or 
immigration. This has improved the completeness of data in the Danish Pancreatic Cancer 
Database. Based on the clinical validation of the latest data, the completeness is above 95% 
 
2.2 Study population 
We initially identified all patients registered with a pancreatic cancer diagnosis in the Danish 
Pancreatic Cancer Database during the study period (n=4,251). We excluded patients who did not 
undergo surgery (n=3,259), without a postoperative specimen registered in the Danish National 
Pathology Registry (n=31), and patients receiving neoadjuvant chemotherapy (n=88), thus leaving 
a study population of 873 patients. The initial treatment plan from the multidisciplinary conference 
was available for 2951 patients (69%) and for 786 (90%) of the study population. For flowchart, see 
the Supplementary Information (Table A.1). 
 
2.3 Definition of waiting time to surgery 
We defined waiting time to surgery in two ways. First, we calculated the time from the date of entry 
into the National Cancer Pathway to the date of surgery. In 2009, The National Cancer Pathways 
were implemented in Denmark to ensure timely cancer diagnosis and treatment within a 
prespecified time interval, which is based on the type of cancer.[4] For example, pancreatic cancer 
patients with a potentially resectable tumor are entitled to be operated within 10 days of decision to 
offer surgical treatment. As the National Cancer Pathway is not activated after neoadjuvant 














were therefore excluded. Second, we calculated the time to surgery from the date of the last 
preoperative computed tomography (CT), or positron emission tomography/computed tomography 
(PET-CT) scan to the date of surgery. Patients with missing information on waiting time were 
excluded from the analysis. Waiting time was grouped into three groups: less than 28 days (<4 
weeks), 28-55 days (4-8 weeks), and 56 days or longer (≥8 weeks). 
 
2.4 Statistical analysis 
Descriptive variables are summarized using means and proportions. For each of the three waiting 
time groups, we calculated the resection rate, defined as the proportion of patients undergoing 
resection divided by the total number of patients. To examine the impact of waiting time to surgery 
on survival, we calculated median survival with associated 95% confidence interval (CI) for patients 
undergoing resection and for patients undergoing a palliative procedure. Survival was estimated 
according to the Kaplan-Meier estimator. For the survival analyses, we followed patients from the 
date of surgery to death, emigration, or study end (31 October, 2017) whichever occurred first. 
Statistical analyses were performed using Stata version 15 (StataCorp LP, College Station, TX, 
USA). 
 
2.5 Ethical considerations 
This study was approved by the Danish Data Protection Agency, Region of Southern Denmark 



















We included 873 patients undergoing surgery for pancreatic cancer during the study period. Mean 
age was 67 years (range: 35-86 years), and approximately half were men (Table 1). The vast 
majority (92%) had a ductal adenocarcinoma. Resection was performed in 701 patients (80%); the 
remaining 172 patients (20%) underwent an explorative laparotomy or palliative surgery. Among 
the 701 patients undergoing resection, 484 (69%) had a Whipple procedure (Table 2). Seventy-
four percent of the patients had stage IIb or stage III disease at pathological examination. We had 
information on preoperative T- and N-stage in approximately one-third of the population. There 
were no differences in the distribution of T- or N-stages regarding waiting time to surgery (Table 4). 
 
3.2 Waiting time 
3.2.1 National Cancer Pathway 
In total, 652 patients (75%) had a registration in the National Cancer Pathway. Median waiting time 
to surgery was 31 days. Eighty-eight percent of the patients were resected within 55 days from 
diagnosis (Table 3). The proportion of patients older than 70 years was higher among patients 
waiting 28-55 days (45%) and 56 days or longer (53%) compared to patients waiting less than 28 
days (37%). There was no difference in sex or Charlson Comorbidity Index score between the 
three groups. Resection rates and median survival were approximately the same in all three 
groups (Table 3 and Figure 1). 
 
3.2.2 Time from last CT/PET-CT 
In total, 818 patients (94%) had registration of a preoperative CT and PET-CT scan in the Danish 
National Patient Registry. Median waiting time to surgery was 32 days. Tumor was resected in 
91% of the patients within 55 days from diagnosis (Table 3). There was no sex difference between 
the three waiting groups, but the proportion of patients older than 70 years was higher among 
those waiting 28-55 days (43%) and 56 days or longer (51%) compared to patients who waited 














respectively). Resection rates and median survival were approximately the same in all three 
groups (Table 4 and Figure 2). 
 
3.2.3 Multidisciplinary conference 
Based on the partial data from the multidisciplinary conference, 888 patients were scheduled for 
surgery. Of these, 670 (75%) had tumor resection, 116 (13%) exploration / palliative procedure, 
and 102 (11%) never made it to surgery. Of these 102 patients, 51 (50%) had a new CT within 6 
weeks of the multidisciplinary conference, whereas the remaining 51 patients had no further 
imaging within 6 weeks. 
 
4. DISCUSSION 
In the present study of 873 patients undergoing resection or palliative surgery for pancreatic cancer 
within 8 weeks from diagnosis, no association between time to surgery and survival was observed. 
Median survival rates were comparable to those previously reported following pancreatic cancer 
surgery.[2] Similarly, we observed no differences in resection rates between the three waiting time 
groups. 
Because of the aggressive biology of pancreatic tumors,[12] instant cancer surgery should 
be a priority for several reasons. Apart from the psychological factor and the stress patients may 
feel, the need to avoid progression and dissemination of the disease calls for an accelerated time 
to operation. However, our results did neither find a relation between the present time to surgery 
and the resectability nor the median survival. To some extent, our findings agree with some 
previous reports. Raptis et al. found that implementation of the National Cancer Waits Target of 62 
days in the United Kingdom did neither improve operability, resectability, nor survival rates in 355 
patients with pancreatic cancer.[5] Nor did McLean et al. observe a difference in resectability rates 
or survival according to waiting time in 119 patients who underwent operation for periampullary 
adenocarcinoma.[7] They did, however, show that the proportion of T4 tumors was higher in 














Marchegiani et al., who also found that waiting time more than 30 days was associated with an 
increase in tumor size.[6] However, this did not translate into impaired survival in this study either. 
Contrary to these findings, Mirkin et al. in a cohort study of 14,807 patients with stage I-II 
pancreatic cancer found that a waiting time of 1-2 weeks was associated with poorer survival in a 
crude analysis, although the effect was modest (hazard ratio 1.12; 95% CI: 1.05-1.19).[13] 
However, they did also find that patients waiting 8-12 weeks were less likely to have negative 
surgical margins or undergo adjuvant therapy, both of which potentially can affect prognosis. A 
major drawback of the study by Mirkin et al. is that they followed patients from the date of 
diagnosis rather than the day of surgery, introducing a classical example of immortal time bias.[14] 
Furthermore, they included histology codes for intestinal cancers and cholangiocarcinomas, thus 
limiting comparison to other studies. 
The present study has some important strengths. We defined waiting times in two way; by 
the National Cancer Pathway and by the last preoperative radiologic examination. Due to 
administrative causes, the National Cancer Pathway may remain inactivated in some patients 
(25% in this study). However, only 6% of the patients did not have registration of a preoperative 
radiologic examination. We observed similar resection and survival rates in both groups, limiting 
the risk of potential selection bias. Furthermore, the homogeneity in the National Cancer Pathways 
and the universal tax-financed healthcare system in Denmark also mitigates potential selection 
bias. 
Some limitations should be noted. First, most importantly, some patients may have had 
their planned surgical procedure cancelled during the waiting time. Based on the partial data on 
multidisciplinary conference, this was the case for 11% of the patients. This could be caused by 
either tumor progression or or clinical deterioration, both precluding surgical treatment. Given that 
the multidisciplinary conference is often based solely on imaging without full information on the 
patients, some will be found subsequently to be non-operable. It is not possible to fully distinguish 
between non-operability and progression based on data from the registry. But the lack of further 














having tumor progression. As we did not have clinical information of these patients, this could incur 
a selection bias, as patients in the long waiting time group may have smaller tumors, leading to a 
potential better prognosis. However, there were only minuscule differences in preoperative T- and 
N-stage between the three groups. Thus, the potential selection bias caused by such a difference 
is of limited concern, but not eliminated as we had information on preoperative T- and N-stage in 
around one-third of the patients. Second, we had no information on other factors such as resection 
margins, lymph node status, tumor differentiation, and performance status, which affect prognosis 
and may be skewedly distributed between the waiting time groups.[15, 16] Third, we did not have 
information on the reasons for the waiting time (e.g. preoperative optimization, additional 
diagnostic workup, administrative reasons etc.). 
 Our study has substantial clinical implications. Despite patients’ and physicians’ 
perceptions of the opposite, resection rates and survival rates were unaffected by waiting time to 
surgery in patients undergoing pancreatic cancer surgery. We emphasize that healthcare policies 
by political decision-makers should be based on available evidence rather than subjective 
opinions. The substantial psychological distress of the waiting time to surgery for patients with a 
highly malignant disease and their relatives[17] should however not be disregarded as an 




In conclusion, our findings suggest that longer waiting times to surgery within 8 weeks from 
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Table 1. Descriptive characteristics of 873 patients undergoing surgery for pancreatic 
cancer. 
 N (%) 
Age, years, mean (range) 67 (35-86) 
Age group  
 <50 43 (5%) 
 50-69 472 (54%) 
 70+ 358 (41%) 
Sex  
 Men 476 (55%) 
 Women 397 (45%) 
Charlson Comorbidity Index Score  
 Low (0) 362 (41%) 
 Moderate (1-2) 310 (36%) 
 Severe (>2) 201 (23%) 
Tumor histology  
 Adenocarcinoma 804 (92%) 
 Mucinous adenocarcinoma 13 (1%) 
 IPMN 7 (1%) 
 Adenosquamous carcinoma 17 (2%) 
 Acinar cell carcinoma 2 (0%) 
 Undifferentiated carcinoma 12 (1%) 
 Malignant tumor cells 14 (2%) 
 Other 4 (0%) 
Type of surgery  
 Resection 701 (80%) 
















Table 2. Characteristics of 701 patients resected for pancreatic cancer. 
 N (%) 
Procedure  
 Pancreaticoduodenectomy (Whipple) 484 (69%) 
 Distal pancreatectomy 89 (13%) 
 Total pancreatectomy 127 (18%) 
AJCC stage  
 Stage Ia 20 (3%) 
 Stage Ib 37 (5%) 
 Stage IIa 133 (19%) 
 Stage IIb 391 (56%) 
 Stage III 30 (4%) 















Table 3. Preoperative T- and N-stage according to waiting time to surgery. 
 National Cancer Pathwaya 
(n=652) 
Time since last CT/PET-CTb 
(n=818) 
 <28 days 28-55 days ≥56 days <28 days 28-55 days ≥56 days 
Total 278 (43%) 297 (46%) 77 (12%) 321 (39%) 420 (51%) 77 (9%) 
T-stage       
 T1 17 (12%) 7 (8%) 2 (7%) 19 (11%) 10 (10%) 3 (16%) 
 T2 51 (37%) 36 (40%) 8 (30%) 64 (35%) 39 (38%) 9 (47%) 
 T3 57 (42%) 39 (43%) 15 (56%) 84 (46%) 45 (44%) 6 (32%) 
 T4 12 (9%) 8 (9%) 2 (7%) 14 (8%) 9 (9%) 1 (5%) 
N-stage       
 N0 78 (70%) 44 (59%) 14 (64%) 110 (72%) 48 (56%) 11 (65%) 
 N1 34 (30%) 30 (41%) 8 (36%) 43 (28%) 37 (44%) 6 (35%) 
a T-stage: Missing data on 47 patients, 351 patients staged as Tx; N-stage: Missing data on 47 patients, 397 patients staged as Nx. 














Table 4. Resection and survival rates according to waiting time to surgery. 
 National Cancer Pathway 
(n=652) 
Time since last CT/PET-CT 
(n=818) 
 <28 days 28-55 days ≥56 days <28 days 28-55 days ≥56 days 
Total 278 (43%) 297 (46%) 77 (12%) 321 (39%) 420 (51%) 77 (9%) 
Surgery       
 Resection 236 (85%) 248 (84%) 61 (79%) 254 (79%) 334 (80%) 63 (82%) 
 Exploration/palliation 42 (15%) 49 (17%) 16 (21%) 67 (21%) 86 (20%) 14 (18%) 
Median survival, months       
 Resection 22.3 (18.1-27.3) 25.1 (21.0-31.3) 20.7 (14.0-26.1) 22.1 (19.3-25.9) 22.0 (17.4-26.2) 21.8 (16.3-26.1) 















Figure 1. Kaplan-Meier survival curves for patients registered in the National Cancer 




















Figure 2. Kaplan-Meier survival curves for patients registered with a preoperative CT/PET-
CT scan in the Danish National Patient Registry. A: Survival after resection; B: Survival after 
exploration or palliative surgery. 
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